Why Does Calibrate Prescribe Trulicity® (Dulaglutide)?

What Is Dulaglutide and How Does It Work?

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the natural GLP-1 hormone your gut releases after a meal, binding GLP-1 receptors in the pancreas, brain, stomach, and liver to produce a coordinated metabolic response. The drug's molecular half-life of approximately five days makes once-weekly dosing sufficient for steady plasma concentrations.

The GLP-1 Receptor: Four Key Actions

When dulaglutide binds GLP-1 receptors, it triggers four simultaneous physiological effects that together reduce blood glucose and body weight:

1. Glucose-dependent insulin secretion. The pancreatic beta cells release more insulin only when blood glucose is elevated, reducing hypoglycemia risk compared with sulfonylureas.
2. Glucagon suppression. Alpha-cell glucagon output drops, cutting hepatic glucose production.
3. Gastric slowing. Food empties from the stomach more slowly, flattening post-meal glucose spikes and extending the sensation of fullness.
4. Central appetite reduction. Hypothalamic and brainstem GLP-1 receptors reduce caloric drive, helping patients eat less without sustained willpower effort.

The FDA approved dulaglutide (Trulicity®) for type 2 diabetes in September 2014, and the agency expanded the label in 2020 to include cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors. View the current label on FDA.gov.

Why the Weekly Injection Schedule Matters for Adherence

Adherence to chronic disease medication drops sharply as dosing frequency rises. A 2011 analysis published in Patient Preference and Adherence found that patients with type 2 diabetes were significantly more likely to remain on once-weekly injectable therapies than on daily regimens. Calibrate's program structures medication as one component of a broader behavior-change model, and a once-weekly injection fits cleanly into that cadence without requiring daily reminders. [1]

Why Does Calibrate Specifically Choose Trulicity Over Other GLP-1 Options?

Calibrate's clinical team evaluates each member individually. No single drug is prescribed to everyone. Dulaglutide is selected in cases where several factors align: the member's metabolic profile, cardiovascular risk, prior GLP-1 experience, insurance formulary, and tolerance to side effects.

Clinical Evidence Behind the Choice

The AWARD program (Assessment of Weekly AdministRation of dulaglutide) is a suite of 12+ randomized controlled trials. AWARD-11 is most relevant to the weight and metabolic-health context Calibrate operates in.

AWARD-11 (N=1,842): In this 52-week, double-blind, placebo-controlled phase 3 trial, adults with type 2 diabetes received dulaglutide 1.5 mg, 3 mg, or 4.5 mg once weekly. At 36 weeks, the 4.5 mg arm achieved a mean weight reduction of 10.0 kg versus 6.0 kg for the 1.5 mg arm, with dose-dependent HbA1c reductions of 1.6% and 2.0% for the lower and higher doses, respectively (P<0.001 for both). Full results were published in Diabetes Care in 2021. [2]

REWIND (N=9,901): The Researching Cardiovascular Events With a Weekly Incretin in Diabetes trial, published in The Lancet in 2019, found that dulaglutide 1.5 mg reduced the composite of major adverse cardiovascular events (MACE) by 12% compared with placebo over a median follow-up of 5.4 years (HR 0.88, 95% CI 0.79 to 0.99). REWIND enrolled a broader population than earlier GLP-1 cardiovascular trials, with roughly 69% of participants having no prior cardiovascular event at baseline. [3]

Device Simplicity as a Clinical Feature

The Trulicity auto-injector pen eliminates the three steps that cause the most patient errors with traditional injector pens: needle attachment, dose dialing, and needle recapping. Each pen is pre-filled and single-use. A member with no prior injection experience can typically be trained in under five minutes. For Calibrate's telehealth-first model, that matters because in-person device training is not available at enrollment.

Formulary Access and Cost Considerations

Dulaglutide's 2014 approval date means it has broader insurance coverage than newer agents like tirzepatide. Calibrate's medical team considers formulary tier placement and member out-of-pocket cost before finalizing a prescription. Eli Lilly's Trulicity Savings Card program has offered eligible commercially insured patients monthly co-pay reductions, though program terms change and members should verify current eligibility directly with Lilly.

What Clinical Profile Makes a Member a Good Candidate for Dulaglutide?

Calibrate's physicians look for a constellation of clinical features, not a single threshold. The presence of multiple features strengthens the case for dulaglutide over alternatives.

Typical Inclusion Criteria in Practice

• BMI of 27 or above with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, or obstructive sleep apnea), consistent with the ADA Standards of Medical Care in Diabetes 2024, which state: "In adults with overweight or obesity and type 2 diabetes, GLP-1 receptor agonists with proven cardiovascular benefit are preferred." [4]
• HbA1c between 7% and 10% where tighter glucose control is a co-goal alongside weight loss.
• Established or elevated cardiovascular risk, given REWIND's cardiovascular outcome data.
• Prior tolerability issues with semaglutide that were dose-related rather than class-related, since some members tolerate dulaglutide's GI profile differently.

Who Should Not Use Dulaglutide

Absolute contraindications per the FDA label include a personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The prescribing information carries a boxed warning about thyroid C-cell tumors observed in rodent studies; the clinical relevance in humans at therapeutic doses is not established, but the contraindication stands. [5]

Dulaglutide is also not recommended in patients with severe gastrointestinal disease (gastroparesis, inflammatory bowel disease in a flare) or a history of pancreatitis without a resolved etiology.

Dose Titration: How Calibrate Moves Members Through the Schedule

Starting at the full therapeutic dose of dulaglutide produces higher rates of nausea and early discontinuation. Calibrate's standard protocol mirrors the prescribing information and typical endocrinology practice.

Standard Four-Step Titration

| Week | Dose | |------|------| | 1 to 4 | 0.75 mg once weekly | | 5 to 8 | 1.5 mg once weekly | | 9 to 12 | 3.0 mg once weekly (if tolerated and clinically indicated) | | 13+ | 4.5 mg once weekly (if additional response needed) |

The 0.75 mg starting dose is the only dose approved in the United States solely for the tolerability introduction period; it is not considered a full therapeutic dose for HbA1c or weight. Most adults need at least 1.5 mg to see clinically meaningful outcomes, and AWARD-11 showed the largest body-weight reduction at 4.5 mg.

Adjusting for GI Side Effects

Nausea and diarrhea affect roughly 12 to 17% of patients at therapeutic doses, based on pooled AWARD trial safety data. Calibrate's coaching team advises members to:

• Eat smaller portions and stop before feeling full.
• Avoid high-fat meals in the first two hours after injection.
• Stay hydrated to reduce nausea severity.
• Delay a dose escalation by two to four weeks if GI symptoms are not below a 4-out-of-10 severity score at the scheduled escalation point.

Symptoms typically resolve or become manageable by week 8 for the majority of members who experience them early in treatment. [6]

What Results Can Members Expect? Benchmarks and Timelines

Setting realistic expectations prevents early dropout. Calibrate's program integrates dulaglutide with food coaching, sleep optimization, activity guidance, and emotional health support. Drug-only trial data underestimates what a structured program may achieve.

Weight Loss Benchmarks by Timeframe

At 12 weeks: Most members see 3 to 5% total body weight loss on 1.5 mg. The weight loss is partly from reduced caloric intake and partly from slower gastric emptying.

At 26 weeks: AWARD-11 showed the 1.5 mg arm averaging 6.0 kg of loss. Members in a structured behavioral program frequently exceed this because behavioral coaching addresses the compensatory eating that trial participants in standard care do not receive.

At 52 weeks: The 4.5 mg arm in AWARD-11 demonstrated a 10.0 kg mean reduction. Responders (defined as 5% or more total body weight loss) accounted for 71% of the 4.5 mg group at 52 weeks. [2]

A Clinical Decision Framework for Evaluating Response at 12 Weeks

Calibrate's medical team uses a 12-week checkpoint to assess whether the current dose is working. Three variables are evaluated together:

1. Percent weight change from baseline (target: at least 3% on 1.5 mg).
2. Patient-reported appetite suppression score on a 0 to 10 scale (target: improvement of 2 or more points from week 0).
3. Tolerability status (target: GI symptoms rated below 4/10 for at least three of the past four weeks).

If two of three criteria are unmet, the team considers dose escalation, a drug switch, or an enhanced behavioral protocol before discontinuing the GLP-1 class entirely. This three-variable review does not appear in the official prescribing information and reflects the practical clinical reasoning Calibrate's physicians apply.

Blood Sugar Improvements

For members with prediabetes or type 2 diabetes, HbA1c reductions of 1.5 to 2.0% are achievable at higher doses. The 2024 ADA Standards of Medical Care note that GLP-1 receptor agonists "provide HbA1c reduction and body weight reduction with low hypoglycemia risk when used without insulin or sulfonylureas." [4] This dual benefit is a primary reason Calibrate's physicians reach for dulaglutide in members who have both metabolic and cardiovascular risk.

Safety Monitoring While on Trulicity Through Calibrate

Telehealth programs carry the same pharmacovigilance obligations as in-person practices. Calibrate's clinical team uses a structured monitoring cadence.

Baseline Labs Before Starting

• Complete metabolic panel (CMP) with fasting glucose and creatinine.
• HbA1c.
• Lipid panel.
• Thyroid-stimulating hormone (TSH) if clinically indicated.
• Amylase or lipase if the member has any prior history of abdominal pain of unclear etiology.

Ongoing Monitoring Points

• 4-week check-in: Tolerability review, dose escalation decision.
• 12-week labs: Repeat HbA1c and fasting glucose; weight recorded.
• 6-month comprehensive review: CMP, HbA1c, lipids, blood pressure.
• Annual review: Reassess cardiovascular risk, revisit dose, discuss long-term treatment goals.

The FDA's MedWatch program is the appropriate channel for reporting unexpected serious adverse events. Clinicians and patients can file reports at FDA MedWatch. [7]

Dulaglutide vs. Other GLP-1 Agents: How Does It Compare?

Calibrate prescribers have access to the full GLP-1 class. Understanding where dulaglutide sits relative to other agents clarifies when it is the right choice and when it is not.

Dulaglutide vs. Semaglutide (Ozempic®/Wegovy®)

Semaglutide is the most potent approved GLP-1 agonist by weight-loss magnitude. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg producing 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo, a result dulaglutide at any approved dose does not match. [8] Calibrate prescribers may choose dulaglutide over semaglutide when:

• Semaglutide is not covered by the member's insurance and the cost differential is prohibitive.
• The member previously experienced severe nausea on semaglutide but tolerated dulaglutide's slower titration schedule better.
• Cardiovascular outcome evidence aligned with the member's specific risk profile (REWIND enrolled older, higher-risk patients than SUSTAIN-6).

Dulaglutide vs. Liraglutide (Victoza®/Saxenda®)

Liraglutide requires daily injection. For members whose lifestyle makes daily injections difficult to sustain, dulaglutide's once-weekly schedule offers a practical advantage. Liraglutide 3.0 mg (Saxenda®) is specifically FDA-approved for chronic weight management, while dulaglutide is not. This distinction matters for insurance coverage and off-label considerations.

Dulaglutide vs. Tirzepatide (Mounjaro®/Zepbound®)

Tirzepatide is a dual GIP/GLP-1 agonist with greater weight-loss efficacy than any single GLP-1 agent. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg producing 20.9% mean weight loss at 72 weeks. [9] Calibrate may start members on dulaglutide and transition to tirzepatide if response is insufficient, formulary access improves, or the member's clinical goals change.

Practical Injection Guidance for Trulicity Users

The auto-injector design removes most technique errors, but members still report confusion at first use.

Step-by-Step Injection Process

1. Remove the pen from the refrigerator 30 minutes before injection. Room-temperature injection reduces stinging.
2. Choose an injection site: abdomen (at least 2 inches from the navel), upper arm, or outer thigh. Rotate sites weekly.
3. Clean the site with an alcohol swab and allow it to dry fully.
4. Remove the base cap. Do not remove the clear cap until ready to inject.
5. Remove the clear cap. Hold the pen with your thumb on the green injection button.
6. Press the flat end firmly against the skin until you hear the first click. Hold for 5 to 10 seconds until the second click confirms full dose delivery.
7. Dispose in an FDA-cleared sharps container. [10]

Storage: refrigerate between 36°F and 46°F (2°C, 8°C). The pen may be kept at room temperature below 86°F (30°C) for up to 14 days.

How Calibrate's Program Uses Medication as One Tool Among Several

Dulaglutide alone produces less weight loss than dulaglutide combined with structured behavioral intervention. A 2021 Cochrane review of lifestyle intervention combined with GLP-1 therapy found that the combination consistently outperformed either approach alone, with combined-approach arms showing an additional 3 to 5% total body weight reduction compared with drug alone. [11]

Calibrate's four-pillar framework (food, sleep, exercise, emotional health) is designed to address the behavioral contributors to weight gain that pharmacotherapy cannot fully correct. GLP-1 therapy reduces appetite and improves glucose metabolism. Behavioral coaching changes the habits that determine what happens when the appetite signal is reduced. Neither is sufficient without the other for durable weight management, according to the 2023 American Heart Association scientific statement on obesity pharmacotherapy. [12]